MTOR and anemia (phenotype): Drugs targeting PI3K/Akt/mTOR pathway were reported to cause hyperglycemia and hyperlipidemia, bone marrow suppression (particularly – anemia, thrombocytopenia, and neutropenia), stomatitis, hepatotoxicity, and pneumonitis [153].